Page 1006 - Williams Hematology ( PDFDrive )

980 Part VII: Neutrophils, Eosinophils, Basophils, and Mast Cells Chapter 63: Basophils, Mast Cells, and Related Disorders 981

166. Bowers HM Jr, Mahapatro RC, Kennedy JW: Numbers of mast cells in the axillary 200. Akin C, Soto D, Brittain E, et al: Tryptase haplotype in mastocytosis: Relationship to dis-
lymph nodes of breast cancer patients. Cancer 43:568–573, 1979. ease variant and diagnostic utility of total tryptase levels. Clin Immunol 123:268–271, 2007.
167. Yoo D, Lessin LS, Jensen WN: Bone-marrow mast cells in lymphoproliferative disor- 201. Kristensen T, Vestergaard H, Bindslev-Jensen C, et al: Sensitive KIT D816V mutation
ders. Ann Intern Med 88:753–757, 1978. analysis of blood as a diagnostic test in mastocytosis. Am J Hematol 89:493–498, 2014.
168. Yoo D, Lessin LS: Bone marrow mast cell content in preleukemic syndrome. Am J Med 202. Siebenhaar F, Akin C, Bindslev-Jensen C, et al: Treatment strategies in mastocytosis.
73:539–542, 1982. Immunol Allergy Clin North Am 34:433–447, 2014.
169. Fohlmeister I, Reber T, Fischer R: Bone marrow mast cell reaction in preleukaemic 203. Frieri M, Alling DW, Metcalfe DD: Comparison of the therapeutic efficacy of cromolyn
myelodysplasia and in aplastic anaemia. Virchows Arch A Pathol Anat Histopathol sodium with that of combined chlorpheniramine and cimetidine in systemic mastocy-
405:503–509, 1985. tosis. Results of a double-blind clinical trial. Am J Med 78:9–14, 1985.
170. Unna PG: Beitrage zur anatomic und pathogenese der urticaria simplex und pigmen- 204. Robyn J, Metcalfe DD: Systemic mastocytosis. Adv Immunol 89:169–243, 2006.
tosa. Mscch Prakt Dermatol 6:EH1, 1887. 205. Soter NA, Austen KF, Wasserman SI: Oral disodium cromoglycate in the treatment of
171. Nettleship E, Tay W, Med J: Rare forms of urticaria. Br Med J 2:323–330, 1869. systemic mastocytosis. N Engl J Med 301:465–469, 1979.
172. Sangster A: An anomalous mottled rash, accompanied by pruritus, factious urticaria 206. Czarnetzki BM: A double-blind cross-over study of the effect of ketotifen in urticaria
and pigmentation, “urticaria pigmentosa (?).” Trans Clin Soc Lond 11:161, 1878. pigmentosa. Dermatologica 166:44–47, 1983.
173. Ellis JM: Urticaria pigmentosa; a report of a case with autopsy. Arch Pathol 48:426–435, 207. Kettelhut BV, Berkebile C, Bradley D, et al: A double-blind, placebo-controlled,
1949. crossover trial of ketotifen versus hydroxyzine in the treatment of pediatric mastocytosis.
174. Carter MC, Metcalfe DD, Komarow HD: Mastocytosis. Immunol Allergy Clin North Am J Allergy Clin Immunol 83:866–870, 1989.
34:181–196, 2014. 208. Barton J, Lavker RM, Schechter NM, et al: Treatment of urticaria pigmentosa with cor-
175. Soter NA: Mastocytosis and the skin. Hematol Oncol Clin North Am 14:537–555, vi, ticosteroids. Arch Dermatol 121:1516–1523, 1985.
2000. 209. Kolde G, Frosch PJ, Czarnetzki BM: Response of cutaneous mast cells to PUVA in
176. Horny HP, Metcalfe DD, Bennett JM, et al: Mastocytosis, in WHO Classification of Tumours patients with urticaria pigmentosa: Histomorphometric, ultrastructural, and biochem-
of Haematopoietic and Lymphoid Tissues edited by Swerdlow SH, Campo E, Harris NL, Jaffe ical investigations. J Invest Dermatol 83:175–178, 1984.
ES, Pileri SA, Stein H, Thiele J, Vardiman JW. p 54. IARC Press, Lyon, 2008. 210. Reisberg IR, Oyakawa S: Mastocytosis with malabsorption, myelofibrosis, and massive
177. Furitsu T, Tsujimura T, Tono T, et al: Identification of mutations in the coding sequence ascites. Am J Gastroenterol 82:54–60, 1987.
of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand- 211. Kluin-Nelemans HC, Jansen JH, Breukelman H, et al: Response to interferon alfa-2b in
independent activation of c-kit product. J Clin Invest 92:1736–1744, 1993. a patient with systemic mastocytosis. N Engl J Med 326:619–623, 1992.
178. Nagata H, Worobec AS, Oh CK, et al: Identification of a point mutation in the catalytic 212. Lim KH, Pardanani A, Tefferi A: KIT and mastocytosis. Acta Haematol 119:194–198,
domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients 2008.
who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S 213. Gromke T, Elmaagacli AH, Ditschkowski M, et al: Delayed graft-versus-mast-cell effect
A 92:10560–10564, 1995. on systemic mastocytosis with associated clonal haematological non-mast cell lineage
179. Longley BJ, Tyrrell L, Lu SZ, et al: Somatic c-KIT activating mutation in urticaria pig- disease after allogeneic transplantation. Bone Marrow Transplant 48:732–733, 2013.
mentosa and aggressive mastocytosis: Establishment of clonality in a human mast cell 214. Fodinger M, Fritsch G, Winkler K, et al: Origin of human mast cells: Development from
neoplasm. Nat Genet 12:312–314, 1996. transplanted hematopoietic stem cells after allogeneic bone marrow transplantation.
180. Nagata H, Okada T, Worobec AS, et al: C-kit mutation in a population of patients with Blood 84:2954–2959, 1994.
mastocytosis. Int Arch Allergy Immunol 113:184–186, 1997. 215. Przepiorka D, Giralt S, Khouri I, et al: Allogeneic marrow transplantation for myelo-
181. Valent P: Mastocytosis: A paradigmatic example of a rare disease with complex biology proliferative disorders other than chronic myelogenous leukemia: Review of forty cases.
and pathology. Am J Cancer Res 3:159–172, 2013. Am J Hematol 57:24–28, 1998.
182. Akin C, Fumo G, Yavuz AS, et al: A novel form of mastocytosis associated with a trans- 216. Nakamura R, Chakrabarti S, Akin C, et al: A pilot study of nonmyeloablative allogeneic
membrane c-kit mutation and response to imatinib. Blood 103:3222–3225, 2004. hematopoietic stem cell transplant for advanced systemic mastocytosis. Bone Marrow
183. Lahortiga I, Akin C, Cools J, et al: Activity of imatinib in systemic mastocytosis with Transplant 37:353–358, 2006.
chronic basophilic leukemia and a PRKG2-PDGFRB fusion. Haematologica 93:49–56, 217. Buchdunger E, Cioffi CL, Law N, et al: Abl protein-tyrosine kinase inhibitor STI571
2008. inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth fac-
184. Hirota S, Isozaki K, Moriyama Y, et al: Gain-of-function mutations of c-kit in human tor receptors. J Pharmacol Exp Ther 295:139–145, 2000.
gastrointestinal stromal tumors. Science 279:577–580, 1998. 218. Druker BJ, Tamura S, Buchdunger E, et al: Effects of a selective inhibitor of the Abl
185. Schwaab J, Schnittger S, Sotlar K, et al: Comprehensive mutational profiling in advanced tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2:561–566, 1996.
systemic mastocytosis. Blood 122:2460–2466, 2013. 219. Ma Y, Zeng S, Metcalfe DD, et al: The c-KIT mutation causing human mastocytosis is
186. Castells M, Metcalfe DD, Escribano L: Diagnosis and treatment of cutaneous mastocy- resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site muta-
tosis in children: Practical recommendations. Am J Clin Dermatol 12:259–270, 2011. tions show different inhibitor sensitivity profiles than wild-type kinases and those with
187. Travis WD, Li CY: Pathology of the lymph node and spleen in systemic mast cell dis- regulatory-type mutations. Blood 99:1741–1744, 2002.
ease. Mod Pathol 1:4–14, 1988. 220. Zermati Y, De Sepulveda P, Feger F, et al: Effect of tyrosine kinase inhibitor STI571 on
188. Mican JM, Di Bisceglie AM, Fong TL, et al: Hepatic involvement in mastocytosis: Clini- the kinase activity of wild-type and various mutated c-kit receptors found in mast cell
copathologic correlations in 41 cases. Hepatology 22:1163–1170, 1995. neoplasms. Oncogene 22:660–664, 2003.
189. Lawrence JB, Friedman BS, Travis WD, et al: Hematologic manifestations of systemic 221. Akin C, Brockow K, D’Ambrosio C, et al: Effects of tyrosine kinase inhibitor STI571 on
mast cell disease: A prospective study of laboratory and morphologic features and their human mast cells bearing wild-type or mutated c-kit. Exp Hematol 31:686–692, 2003.
relation to prognosis. Am J Med 91:612–624, 1991. 222. Pardanani A: Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratifica-
190. Horny HP, Ruck MT, Kaiserling E: Spleen findings in generalized mastocytosis. A clini- tion, and management. Am J Hematol 88:612–624, 2013.
copathologic study. Cancer 70:459–468, 1992. 223. Ustun C, DeRemer DL, Akin C: Tyrosine kinase inhibitors in the treatment of systemic
191. Horny HP, Parwaresch MR, Lennert K: Bone marrow findings in systemic mastocyto- mastocytosis. Leuk Res 35:1143–1152, 2011.
sis. Hum Pathol 16:808–814, 1985. 224. Klion AD, Noel P, Akin C, et al: Elevated serum tryptase levels identify a subset of
192. Ridell B, Olafsson JH, Roupe G, et al: The bone marrow in urticaria pigmentosa and patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome
systemic mastocytosis. Cell composition and mast cell density in relation to urinary associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood
excretion of tele-methylimidazoleacetic acid. Arch Dermatol 122:422–427, 1986. 101:4660–4666, 2003.
193. Kettelhut BV, Parker RI, Travis WD, et al: Hematopathology of the bone marrow in 225. Maric I, Robyn J, Metcalfe DD, et al: KIT D816V-associated systemic mastocytosis with
pediatric cutaneous mastocytosis. A study of 17 patients. Am J Clin Pathol 91:558–562, eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are dis-
1989. tinct entities. J Allergy Clin Immunol 120:680–687, 2007.
194. Parker RI: Hematologic aspects of systemic mastocytosis. Hematol Oncol Clin North 226. Valent P, Akin C, Escribano L, et al: Standards and standardization in mastocytosis:
Am 14:557–568, 2000. Consensus statements on diagnostics, treatment recommendations and response crite-
195. Valent P, Sotlar K, Sperr WR, et al: Refined diagnostic criteria and classification of mast ria. Eur J Clin Invest 37:435–453, 2007.
cell leukemia (MCL) and myelomastocytic leukemia (MML): A consensus proposal. 227. Akin C, Valent P, Metcalfe DD: Mast cell activation syndrome: Proposed diagnostic
Ann Oncol 25:1691–1700, 2014. criteria. J Allergy Clin Immunol 126:1099–104 e4, 2010.
196. Yang F, Tran TA, Carlson JA, et al: Paraffin section immunophenotype of cutaneous and 228. Valent P, Akin C, Arock M, et al: Definitions, criteria and global classification of mast
extracutaneous mast cell disease: Comparison to other hematopoietic neoplasms. Am J cell disorders with special reference to mast cell activation syndromes: A consensus
Surg Pathol 24:703–709, 2000. proposal. Int Arch Allergy Immunol 157:215–225, 2012.
197. Escribano L, Diaz-Agustin B, Lopez A, et al: Immunophenotypic analysis of mast cells 229. Friedman B, Darling G, Norton J, et al: Splenectomy in the management of systemic
in mastocytosis: When and how to do it. Proposals of the Spanish Network on Masto- mast cell disease. Surgery 107:94–100, 1990.
cytosis (REMA). Cytometry B Clin Cytom 58:1–8, 2004. 230. Brockow K, Scott LM, Worobec AS, et al: Regression of urticaria pigmentosa in adult
198. Brockow K, Jofer C, Behrendt H, et al: Anaphylaxis in patients with mastocytosis: A study patients with systemic mastocytosis: Correlation with clinical patterns of disease. Arch
on history, clinical features and risk factors in 120 patients. Allergy 63:226–232, 2008. Dermatol 138:785–790, 2002.
199. Cherner JA, Jensen RT, Dubois A, et al: Gastrointestinal dysfunction in systemic mas- 231. Valentini CG, Rondoni M, Pogliani EM, et al: Mast cell leukemia: A report of ten cases.
tocytosis. A prospective study. Gastroenterology 95:657–667, 1988. Ann Hematol 87:505–508, 2008.

Kaushansky_chapter 63_p0965-0982.indd 981 9/18/15 11:01 PM